key: cord-0694605-haxguqxj
authors: Jenča, Dominik; Melenovský, Vojtěch; Stehlik, Josef; Staněk, Vladimír; Kettner, Jiří; Kautzner, Josef; Adámková, Věra; Wohlfahrt, Peter
title: Heart failure after myocardial infarction: incidence and predictors
date: 2020-12-14
journal: ESC Heart Fail
DOI: 10.1002/ehf2.13144
sha: c92ad52ca9e415cf87dbdfad998620d25ccf0ac1
doc_id: 694605
cord_uid: haxguqxj

AIMS: The aim of the present paper was to provide an up‐to‐date view on epidemiology and risk factors of heart failure (HF) development after myocardial infarction. METHODS AND RESULTS: Based on literature review, several clinical risk factors and biochemical, genetic, and imaging biomarkers were identified to predict the risk of HF development after myocardial infarction. CONCLUSIONS: Heart failure is still a frequent complication of myocardial infarction. Timely identification of subjects at risk for HF development using a multimodality approach, and early initiation of guideline‐directed HF therapy in these patients, can decrease the HF burden.

Despite the remarkable advances in the treatment of coronary artery disease and acute myocardial infarction (MI) over the past two decades, MI remains the most common cause of heart failure (HF). 1 According to the time sequence of MI occurrence and HF development, three clinical presentations differing in pathophysiology, clinical characteristics, and outcomes can be identified: (i) HF onset at the time of MI presentation, (ii) HF developing during hospitalization for MI, and (iii) HF onset after discharge from the index hospitalization.

Heart failure developing at the time of myocardial infarction hospitalization

The factors that contribute to the pathogenesis of HF development at the time of the MI hospitalization include myocardial compromise due to myocardial necrosis, myocardial stunning, and mechanical complications such as papillary muscle rupture, ventricular septal defect, and ventricular free wall rupture. Within 30 min of ischaemia, cardiomyocyte structural changes and oedema develop, leading to progressive myocyte death after 3 h of ischaemia. Reperfusion itself causes a second wave of injury through the production of reactive oxygen species. Despite successful epicardial reperfusion, the embolization of thrombotic debris leads to ongoing microvascular dysfunction and myocardial ischaemia. 2 The inflammatory response to myocyte death also contributes to HF development. Furthermore, HF at this stage can be also triggered by exacerbation of pre-existing HF and comorbidities, for example, anaemia, chronic kidney disease (CKD), or chronic obstructive pulmonary disease.

Opposing trajectories of HF incidence presenting at MI admission and during a hospital stay have been observed in the last decades. While the proportion of HF cases at MI admission has increased (from 4% in 1992-1996 3 to 12-13% in 2001-2011 4, 5 ), the proportion of HF cases developing during the hospital stay has decreased (from 39% 3 to 4-28% [4] [5] [6] ). The increase in HF at MI presentation may be explained by recent improvements in pre-hospital care, which led to a decrease in out of hospital mortality. 7,8 On the other hand, the decrease in in-hospital HF may be caused by the introduction of percutaneous coronary intervention (PCI), which leads to more substantial myocardial salvage as compared with thrombolysis. In the nationwide SWEDEHEART registry, 6 the incidence of in-hospital HF complicating MI has fallen from 46% in the thrombolytic era (the year 1996) to 28% in PCI era (the year 2008) (Figure 1 ). Higher myocardial salvage by PCI can also explain the increase in the proportion of patients with HF with preserved ejection fraction, which increased from 18% in 1998 to 30% in 2008. The second explanation for the in-hospital HF decrease may be the change in MI diagnosis, which is currently based on troponin level and allows the detection of less severe MI cases with a lower risk of HF development.

Heart failure developing after MI hospitalization is a consequence of cardiomyocyte death and scar formation, which triggers chronic neurohumoral activation (reninangiotensin-aldosterone and sympathetic nervous system up-regulation) and ventricular remodelling. Left ventricular (LV) remodelling is more pronounced in men, patients with larger infarct size, and late or unsuccessful reperfusion of epicardial or microvascular bed. 9 Ventricular remodelling changes ventricular geometry and leads to wall thinning, ischaemic mitral regurgitation, and further cardiomyocyte loss.

Heart failure development after hospital discharge is very prevalent. It is diagnosed in approximately 13% of patients at 30 days and 20-30% at 1 year after discharge for MI. 10, 11 The incidence of HF after MI discharge is highest in the first months, and then it drops and remains stable at a rate of 1.3-2.2% per year afterwards. 11

The development of HF after MI has a significant impact on outcomes, regardless of the HF type. 12 Among patients with a history of MI, HF development increases total mortality risk three-fold and cardiovascular mortality four-fold. The timing of HF development also has an impact on adverse events. HF developing more than 3 days after MI is associated with a 43% higher mortality risk as compared with patients with HF developing in the first 3 days after MI. 12 This may be explained by different risk factors and mechanisms leading to HF at different time points.

The need for heart failure screening and prevention As recognized by both the European Society of Cardiology 13 and the American Heart Association, 14 HF prevention is an urgent public health need. The population of patients after MI represent a high-risk group for HF development, in which HF screening and prevention is of particular importance. Missed or delayed diagnosis of HF compromises patient prognosis and increases therapy costs. This underscores the need for close follow-up of MI patients at risk for HF development, which has been shown to result in improved patient adherence, higher prescription of recommended therapy, and lower cardiovascular hospitalizations. [15] [16] [17] The present paper reviews risk factors and biomarkers associated with HF development after MI and suggests a multimodality approach for screening ( Figure 2 ). This information is intended to assist clinicians in identifying patients at particular risk of HF development after MI and early initiation of guideline-directed HF therapy in these patients at high risk of adverse clinical events.

The impact of different clinical risk factors on the HF risk after MI is shown in Table 1 .

The incidence of in-hospital HF is three times higher in patients 75-85 years old as compared with those 25-54 years old. After hospital discharge, HF incidence is six times higher in the older age group. 11 After multivariate adjustment, the in-hospital HF risk increases by approximately 50% 5 and postdischarge HF by 20-50% 18-20 for every 10 years of age.

Female sex was found to be independently associated with increased HF risk after MI in some studies, but not in others. 18, 19, [21] [22] [23] In the studies that reported higher risk associated with female sex, the excess HF risk ranged from 15% to 34%. 6, 20, 24 Several reasons may explain higher HF risk in women. Compared with men, female patients presenting with MI are older and have a higher prevalence of co-morbidities and worse functional status. 25 The impact of co-morbidities such as diabetes, hypertriglyceridemia, and metabolic syndrome on cardiovascular risk appears to be higher in women than men. Furthermore, gender disparities in MI presentation 26,27 and less aggressive hospital care of female patients, 27 including the underuse of revascularization, may further contribute to the higher HF risk in women. 28

Multi-vessel disease (MVD) reflects the high atherosclerotic burden with more prominent endothelial dysfunction and systemic inflammation. 29 Patients with MVD are generally older and have diabetes and renal impairment as common co-morbidities. MVD is associated with lower ejection fraction 22,29 and increased risk of major adverse cardiovascular events (MACE), including HF, by 80%. 29 Anterior MI is associated with a higher risk of adverse remodelling 30 and HF. 31 The higher risk of HF associated with anterior MI is caused by the greater magnitude of irreversible LV damage, as compared with other MI locations. 32 Figure 2 Multimodal approach for prediction of heart failure after myocardial infarction (MI). 

Many studies reported that arterial hypertension increases the risk of HF. The excess risk associated with arterial hypertension ranged from 7% to 70%. 6,18,20,21 More common microvascular injury and myocardial haemorrhage contribute to the excess HF risk in patients with arterial hypertension. 35 Furthermore, higher neurohormonal activation and more common LV remodelling was described in hypertensive patients after MI. 36

Higher heart rate A higher heart rate at admission was a risk factor for HF after acute MI in several studies. Chronic kidney disease Chronic kidney disease increases the risk of HF development after MI approximately two-fold. 20 Excess HF risk in CKD can be explained by accelerated atherosclerosis, more common MVD, atypical MI presentation, and lower odds of revascularization, which results in larger infarct size and more severe ventricular dysfunction. Moreover, CKD leads to fluid overload, secondary hypertension, anaemia, chronic inflammation, and alterations of the renin-angiotensin-aldosterone system. 46,47 Lower prescription of evidence-based medications in CKD patients has also been reported. 48

Ischaemic preconditioning and heart failure after myocardial infarction

Preconditioning is the process by which brief, repetitive episodes of ischaemia reduce the size of a subsequent MI. Compared with those without antecedent angina, patients with angina have a decreased risk of HF development during MI, lower risk of mortality or adverse LV remodelling after MI, and enhanced recovery of cardiac contractile function after MI. 49,50 The protective effect of angina has been described up to 3 months prior to MI. 51 The difference in outcomes in patients with and without angina preceding MI may be explained by ischaemic preconditioning or a larger extent of collateral circulation in patients with antecedent angina. Whether the ischaemic preconditioning data could be applied to clinical care to improve outcomes remains to be seen. Remote ischaemic conditioning with transient ischaemia and reperfusion of the arm or leg has been shown in several small randomized controlled trials to reduce myocardial infarct size and increase myocardial salvage in patients with ST-segment elevation MI (STEMI). 52,53 However, in the recent large CONDI-2 trail among 5401 STEMI patients, remote ischaemic conditioning by intermittent ischaemia and reperfusion applied to the arm did not decrease the risk of death or hospitalization for HF. 54

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 likely affects the risk of HF development after MI. However, hard clinical data are still lacking. There are several mechanisms by which COVID-19 pandemic may influence the risk of HF development after MI.

First, the incidence of acute coronary syndrome (ACS) increases in the setting of viral infection, likely due to inflammation-mediated plaque destabilization. The risk in the setting of COVID-19 infection is unknown, but other viruses are associated with a 3-fold to 10-fold increased risk. 55 However, a decrease in MI hospitalizations was observed in several countries, 56-58 with a parallel increase in fatality and complication rates. Also, both patient-related and system-related delays were noted, with a 40% increase in Heart failure after myocardial infarction symptom onset to coronary angiography time during the COVID-19 pandemic. Thus, the absence or delay in coronary revascularization during MI may increase the proportion of patients with HF.

Second, there is growing evidence that COVID-19 leads to direct myocardial injury. Within 24 h from admission for COVID-19, troponin elevation is present in 36% of patients. 59 Among recovering patients evaluated a mean of 71 days after confirmed COVID-19 diagnosis, 78% of patients have demonstrable cardiac involvement via cardiac magnetic resonance imaging (MRI), 76% have detectable high-sensitivity troponin, and 60% have evidence of active myocardial inflammation. 60 The mechanisms responsible for myocardial injury during COVID-19 infection may include inflammation, cytokine storm, hypercoagulable state with formation of microthrombi and macrothrombi, direct viral invasion of the myocardium, and myocardial supply/demand imbalance. 59 MI in the setting of COVID-19 infection likely increases not only the mortality risk 56 but also the risk of subsequent HF development.

Cardiac troponin, a biomarker of choice in MI diagnostics, measured at plateau phase (48-72 h after MI symptom onset) is associated with MRI determined infarct size. 61 Similarly, peak levels of creatine kinase (CK) and CK-MB are associated with infarct size on single-photon emission computed tomography. 62 Several studies have shown the association of troponin or CK-MB level with MACE, including HF. 19,63,64 Yet the association of peak troponin or CK-MB with HF has not been seen in all investigations. 65, 66 Natriuretic peptides Alongside troponin, natriuretic peptides are associated with infarct size and cardiac dysfunction. 67, 68 In addition to the magnitude of natriuretic peptides elevation, 66,69 its pattern is also associated with adverse events. While in some patients the brain natriuretic peptide increase after MI has a monophasic pattern with a peak at 16 h after admission, in others, the rise is biphasic with a second peak at 5 days. Patients demonstrating the biphasic pattern have a higher risk of LV remodelling and HF. 70, 71 Additionally, premorbid N-terminal prohormone brain natriuretic peptide levels, as well as high-sensitivity troponin T levels measured at a median time of 6 years before MI, have also been associated with adverse events, including HF. 72

There is growing evidence that prolongation or expansion of the post-infarction inflammatory response significantly contributes to LV remodelling and HF development. 73 Numerous methods of inflammatory response quantification have shown promise in HF prediction. C-reactive protein level predicted the risk of adverse events after MI, including HF, in several studies. [74] [75] [76] [77] The neutrophil-to-lymphocyte ratio, an indicator of systemic inflammation, predicted MACE and HF in a meta-analysis of 14 studies. 78 Cytokines are strategic regulators of inflammation. In a study of 4939 patients with ACS, pro-inflammatory cytokine interleukin 6 (IL-6) was an independent predictor of MACE and HF. 79 IL-32 is a relatively novel pro-inflammatory cytokine that induces the release of other inflammatory cytokines such as tumour necrosis factor-α, IL-1β, IL-6, IL-8, and IL-18. Xuan et al. showed that IL-32 is an independent predictor of cardiac death and HF among patients after MI. 80

The estimated glomerular filtration rate (eGFR) is independently associated with HF risk after MI. Fox et al. used a creatinine-based MDRD equation for eGFR calculation to show that, after multivariate adjustments, the excess risk of HF attributable to renal dysfunction ranged from 30% to 90% depending on CKD stage. 81 Similar results were reported from the VALIANT study where the risk of HF rose by 10% for each 10 mL/min/1.73 m 2 decrease in eGFR. 18 Cystatin C is a sensitive marker of renal impairment that, unlike creatinine, is not affected by age, sex, and muscle mass. In the SOLID-TIMI 52 study among patients with ACS, cystatin C provided incremental information for risk stratification, including HF hospitalization, independent of other biomarkers including eGFR. 82

Suppressor of tumourigenesis (ST2) is a member of the IL-1 receptor family that is involved in the process of myocardial remodelling and fibrosis., 8384 It has two isoforms: transmembrane ligand and soluble form. Binding of the soluble form (sST2) to IL-33 prevents the beneficial effect of this IL on the reduction of cell death and fibrosis. While several studies demonstrated the prognostic utility of sST2 testing in HF, there is less evidence for the predictive value of sST2 after MI. Among consecutive MI patients from the Mayo Clinic, sST2 elevation was independently associated with excess risk of death and HF. Patients in the upper tertial of sST2 had three-fold the risk of HF as compared with the lowest tertial. Galectin-3, a β-galactoside-binding lectin mainly secreted by activated macrophages, is also reflective of fibrosis and cardiac remodelling in response to myocardial injury. 86 The American College of Cardiology/American Heart Association guidelines recommend measurement of both sST2 and galectin-3 for risk prediction in patients with HF. 87 A recent study suggested an independent predictive value of galectin-3 also among unselected MI patients. In a prospectively enrolled incident MI cohort, galectin-3 was associated with increased risk of death and HF even after adjustment for MI severity, co-morbidities, and sST2. 88

Matrix metalloproteinases (MMPs) are proteolytic enzymes that degrade collagen and other proteins of the extracellular matrix. After MI, MMPs regulate the remodelling process by facilitating extracellular matrix turnover and inflammatory signalling. MMP-8 and MMP-9 were shown to predict LV remodelling 89,90 and adverse outcomes, including HF development. 91 Clusterin is a protein that regulates complement activity, apoptosis, and lipid transport. Proteomic analysis of plasma from patients after the first anterior MI identified increased plasma levels of clusterin to be associated with LV remodelling. 92 Whether clusterin is also associated with the risk HF after MI needs to be determined.

The prognostic utility of serial biomarker measurement and multi-marker approach after MI was evaluated by Reinstadler et al., 93 who measured several biomarkers as aspartate and alanine aminotransferases, high-sensitivity troponin T, N-terminal prohormone brain natriuretic peptide, lactate dehydrogenase, and high-sensitivity C-reactive protein daily for 4 days after admission for an MI. They reported that the peak level of the biomarkers studied was associated with LV remodelling, while the admission value was not. Furthermore, combined biomarker analysis was superior to any of the individual biomarkers. 93 Thus, not only the selection of a biochemical biomarker but also timing of the measurement after MI may be of importance in HF risk prediction.

There is a paucity of data on genetic predictors of HF development after MI.

A recent study using weighted gene co-expression network analysis identified genes BCL3, HCK, PPIF, S100A9, SERPINA1, and TBC1D9B to be involved in the inflammatory response, apoptosis, and HF development after MI. 94 MicroRNAs are products of non-coding DNA transcription consisting of approximately 22 nucleotides that act as significant regulators of mRNA translation. In the heart, they control various processes including cardiac cell death, cardiomyocyte regeneration, and cardiac fibroblast transformation into cardiomyocytes. 95 A study by Niu et al. recognized miR-142-3p as a contributor to HF after MI. 94 Shah et al. identified lower concentrations of miR-17-5p, miR-20a-5p, and miR-106b-5p to be associated with a higher incidence of HF after MI. 96 In a study by Lakhani et al., miRNA-24 and 29a levels were reduced in patients with acute MI and low ejection fraction, whereas miRNA-34a, miRNA-208b, and miRNA-126 were increased in these patients. 97

Echocardiography is a commonly used imaging method after MI. In regard to HF prediction, optimal timing of echocardiography is not well defined, as the early post-MI examination may underestimate systolic function due to myocardial stunning. Therefore, repeated echocardiographic examinations after MI are recommended. 98

Reduced LV ejection fraction (LVEF) is associated with the risk of HF development. 18,21,24 A 5% decrease in LVEF determined by ventriculography performed during the MI hospitalization increases the risk of HF development after the hospital discharge by 12-18%. 22,24 Similarly, a 5% decrease in LVEF evaluated by echocardiography 5-20 months after MI increases the risk of HF by 20%. 18 The wall motion score index (WMSI) reflects wall motion abnormalities better than LVEF because compensatory hyperkinesia of non-affected regions may compensate for the impaired systolic function. 98, 99 In a study of 144 patients with MI, WMSI ≥ 1.5 identified people at increased risk of cardiac death, unstable angina, and HF, independent of LVEF. 100 In a study by Møller et al., each 0.2 increase in WMSI was associated with hazard ratio of 1.21 (95% confidence interval 1.07-1.37, P = 0.002) for HF development and hazard ratio of 1.15 (95% confidence interval 1.10-1.21, P < 0.0001) for mortality. 99 A study by Jurado-Román et al. deemed WMS a more powerful predictor of mortality and HF than LVEF. 101 Right ventricular (RV) dysfunction significantly contributes to HF development after MI. The tricuspid annular plane systolic excursion (TAPSE) is the most commonly used parameter to evaluate RV systolic function. In patients after MI, RV dysfunction defined by TAPSE ≤ 14 mm was able to predict early cardiac events, including cardiogenic shock. 102 However, TAPSE assesses only longitudinal contraction of RV and as such provides only partial information on RV function. Fractional area change reflects RV function better than TAPSE.

In several studies among patients after MI, decreased In several studies, no-reflow after MI was an independent predictor of LV recovery and adverse outcomes including HF. 112, 113 Stress echocardiography Dobutamine stress echo-derived parameters such as infarction zone non-viability and ischaemia/infarction at a distance were identified as independent predictors of adverse outcomes, including HF, in patients 2 to 7 days after MI. 114

Infarct size Magnetic resonance imaging is currently the gold standard imaging modality for quantifying infarct size using late gadolinium enhancement. According to a meta-analysis of studies measuring infarct size by MRI or single-photon emission computed tomography in patients after STEMI, for every 5% increase in MI size, the risk of hospitalization for HF increases by 20%. 115 On the other hand, a recent prospective study showed no additional long-term prognostic value of infarct size measured by MRI over LVEF in patients after non-STEMI. 116 The difference in prognostic value in STEMI and non-STEMI may be explained by a different magnitude of myocardial damage.

Microvascular obstruction refers to the lack of perfusion in the coronary microcirculation, despite revascularization of the epicardial vessels. Microvascular obstruction can be identified as a hypointense core within the area of hyperenhancement on either early (referred to as early microvascular obstruction) or late gadolinium enhancement (late microvascular obstruction). Microvascular obstruction is associated with larger MI size and adverse remodelling. In a recent individual patient data meta-analysis, microvascular obstruction increase by 10% elevated the risk of hospitalization for HF by 80% and all-cause mortality by 114%. 117 

If the microvascular injury after MI is severe and the integrity of microcirculation is compromised, extravasation of red blood cells into the myocardium can occur. Red blood cell extravasation is referred to as intramyocardial haemorrhage and can be detected by MRI as a hypointense zone within the MI core on T2* imaging or mapping. Several studies suggest that iron deposits from red blood cells trigger pro-inflammatory response and lead to adverse LV remodelling. 118, 119 Smaller studies in patients after STEMI suggested that myocardial haemorrhage was more closely associated with adverse outcomes, including HF, than microvascular obstruction. 120 . 121

A MRI substudy of the third Danish Study of Optimal Acute Treatment of Patients with ST-segment Elevation Myocardial Infarction (DANAMI 3) proved that multiple scars (characterized by late gadolinium enhancement in more than one myocardial areas remote from acute infarction area) were associated with almost three-fold risk of all-cause mortality and HF hospitalization after adjustment for clinical risk factors and MI size. 

Molecular imaging is an emerging method studying different phases of the post-MI period at a molecular level. The principle is based on the existence of specific tracers that bind to molecules of interest. Various methods of nuclear medicine have shown potential to predict adverse LV remodelling [e. g. tracers binding to MMP-2 or MMP-9 within the infarct zone, angiotensin-converting enzyme inhibitor (ACEi) and angiotensin receptor antagonist-based tracers, growth factor receptors, and α v β 3 integrin tracers]. 123 Currently, data showing predictive value of these methods for HF prediction after MI are lacking.

Among patients with established HF, various remote monitoring strategies have been tested to detect worsening of HF and reduce the risk of HF readmission. Several implantable 124 (using data from cardioverter defibrillators and cardiac resynchronization therapy) and wearable 125 devices have shown the capability to detect HF exacerbation. However, most of the studies with implantable devices could not detect the mortality benefit of telemonitoring. [126] [127] [128] The exception was IN-TIME trial (Biotronik Home Monitoring technology), which documented improvement of a composite clinical score and particularly all-cause mortality in remote monitoring group of patients. 129 Pooled analysis of the three trials with the same monitoring system with daily transmissions (TRUST, ECOST, and IN-TIME) confirmed 38% and 36% reduction of all-cause mortality and the composite endpoint of all-cause mortality or hospitalization for HF worsening, respectively. The benefit of this form of monitoring appears to be driven by the prevention of HF exacerbation, mainly due to early detection of arrhythmias and/or loss of biventricular pacing. 130 Another technology that was capable to reduce HF hospitalizations was the CardioMEMS device-an implantable pulmonary artery pressure monitor. 131 Yet no remote monitoring study has so far targeted at-risk population after MI.

Beta-blockers Beta-blockers interfere with the harmful effects of sustained activation of the sympathetic nervous system, particularly by blocking the β 1 -adrenergic receptors. Together with ACEi, angiotensin receptor blockers, and statins, beta-blockers indirectly inhibit MMPs. 132 The evidence for the favourable effect of beta-blockers on post-MI outcomes comes mainly from the pre-thrombolytic era. In a meta-analysis of 31 randomized studies, long-term beta-blocker use reduced all-cause mortality after MI by 23%. 133 However, none of the studies specifically involved patients with systolic dysfunction and HF during MI hospitalization. 134 In the SAVE and AIRE studies, which originally analysed the effect of ACEi in MI patients with LV systolic dysfunction, beta-blocker use reduced the risk of progression to severe HF by 21% and 42%, respectively. 135, 136 In the CAPRICORN study, carvedilol administered in MI patients with systolic dysfunction (LVEF < 40%) reduced all-cause mortality by 23% and HF hospitalization by 14% compared with placebo. 134 This effect was additional to ACEi. 134

Activation of the renin-angiotensin-aldosterone system actively participates in the process of LV remodelling, myocardial fibrosis, and HF development after MI. ACEi by blocking conversion of angiotensin I into angiotensin II supresses vasoconstriction and aldosterone secretion mediated by angiotensin II. Angiotensin receptor blockers block this action of angiotensin II by interfering with the binding of angiotensin II to its receptor.

Early initiation of ACEi within 0-36 h from MI symptom onset reduces 30 day mortality and HF by 7% and 4%, respectively. 137 The absolute benefit is greater in high-risk groups (such as Killip Class II/III, heart rate >100 b.p.m. at entry) and anterior MI. Importantly, 40% of the survival benefit occurred on the first day of treatment, underscoring the value of initiating ACEIs early, as long as patients have adequate blood pressure. 137 The positive effect of ACEi post-MI was proved also in long-term studies. [138] [139] [140] ACEIs started between 3 and 16 days post-MI reduce the relative risk of mortality by 26% and readmission for HF by 27%. 141 Angiotensin receptor blockers are used in patients with intolerance of ACEi. Various studies have shown favourable effect of losartan or valsartan on mortality and HF hospitalization. 39, 142 Mineralocorticoid receptor antagonist Aldosterone by its action on distal nephron increases sodium and water reabsorption leading to an expansion of the extracellular fluid. In the heart, mineralocorticoid receptor activation triggers inflammation, hypertrophy, and fibrosis.

Mineralocorticoid receptor antagonist eplerenone was tested in the EPHESUS study, in which patients after MI with LVEF < 40% and HF or diabetes were enrolled. As compared with placebo, eplerenone reduced all-cause mortality and HF hospitalization by 15% and death from cardiovascular causes by 17%. 143 This effect was present only if eplerenone was administered in the first 7 days after MI. 144 Heart failure after myocardial infarction

Statins are lipid-lowering drugs with pleiotropic effects. Besides inhibition of 3-hydroxy-3-methylglutarylcoenzyme A reductase, the key enzyme in cholesterol synthesis, statins exert endothelium-stabilizing, anti-inflammatory, and antiproliferative effects on cells involved in atherosclerosis. 145 In the IDEAL and PROVE IT-TIMI 22 studies, high doses of statin (atorvastatin 80 mg daily) decreased HF risk by 26% and 45% as compared with low to moderate statin dose, respectively. 146, 147 Early administration of statins (within 24 h of hospitalization) is associated with a 2.5-fold risk reduction of HF hospitalization and a three-fold reduction in in-hospital mortality. 148

A decrease in HF after MI since the adoption of PCI has been well documented. 10, [149] [150] [151] In population-based studies from Sweden, Western Australia, Denmark, and Olmsted County in the USA, increase in PCI rates led to 20-41% reduction in HF after MI. 10, [149] [150] [151] Conclusions Development of HF after MI is associated with adverse events, impaired quality of life, and lower survival. As reviewed in this paper, a wide range of clinical, laboratory, and diagnostic findings are associated with HF development after MI. However, precise, cost-effective, and accurate scoring system integrating clinical risk factors, genetics, biomarkers, and imaging methods for HF prediction and prognostication after MI is lacking. Better identification of patients at risk of HF development after MI is needed because timely initiation of guideline-directed HF therapy can reduce the risk of further LV remodelling, morbidity, and mortality.

None declared. 

Epidemiology of heart failure

Myocardial no-reflow in humans

Clinical predictors of heart failure in patients with first acute myocardial infarction

infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial

Approach to acute cardiovascular complications in COVID-19 infection

Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era

Patient response, treatments, and mortality for acute myocardial infarction during the COVID-19 pandemic

The Covid-19 pandemic and the incidence of acute myocardial infarction

Mount Sinai COVID Informatics Center. Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection

Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19)

High-sensitivity troponin T predicts infarct scar characteristics and adverse left ventricular function by cardiac magnetic resonance imaging early after reperfused acute myocardial infarction

Comparison of Troponin T to creatine kinase and to radionuclide cardiac imaging infarct size in patients with ST-elevation myocardial infarction undergoing primary angioplasty

Prognostic value of cardiac troponin T after myocardial infarction: a contemporary community experience

Usefulness of peak troponin-T to predict infarct size and long-term outcome in patients with first acute myocardial infarction after primary percutaneous coronary intervention

High-sensitivity cardiac troponin I and risk of heart failure in patients with

Predictors and prognosis for incident in-hospital heart failure in patients with preserved ejection fraction after first acute myocardial infarction: an observational study

Association of plasma B-type natriuretic peptide concentration with myocardial infarct size in patients with acute myocardial infarction

Predictive value of NT-pro BNP after acute myocardial infarction: relation with acute and chronic infarct size and myocardial function

B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction

Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction

Change of BNP between admission and discharge after ST-elevation myocardial infarction (Killip I) improves risk prediction of heart failure, death, and recurrent myocardial infarction compared to single isolated measurement in addition to the GRACE score

Premorbid levels of high-sensitivity cardiac troponin T and natriuretic peptide and prognosis after incident myocardial infarction

Regulation of the inflammatory response in cardiac repair

Predictive value of high sensitivity C-reactive protein on progression to heart failure occurring after the first myocardial infarction

Predictors and prognosis for incident in-hospital heart failure in patients with preserved ejection fraction after first acute myocardial infarction: an observational study

C-reactive protein levels predict systolic heart failure and outcome in patients with first ST-elevation myocardial infarction treated with coronary angioplasty

PROVE IT-TIMI 22 Investigators. Concentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular death

Predictive value of neutrophil to lymphocyte ratio in patients with acute ST segment elevation myocardial infarction after percutaneous coronary intervention: a meta-analysis

Interleukin-6 and the risk of adverse outcomes in patients after an acute coronary syndrome: observations from the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52) trial

Elevated circulating IL-32 presents a poor prognostic outcome in patients with heart failure after myocardial infarction

Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry

Cystatin C for risk stratification in patients after an acute coronary syndrome

Established and emerging roles of biomarkers in heart failure

Inflammatory cytokines as biomarkers in heart failure

Prognostic value of soluble ST2 after myocardial infarction: a community perspective

Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure

ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America

Galectin-3 levels and outcomes after myocardial infarction: a population-based study

Serum MMP-8: a novel indicator of left ventricular remodeling and cardiac outcome in patients after acute myocardial infarction

Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction

Matrix metalloproteinase-9 is a marker of heart failure after acute myocardial infarction

Expression and implication of clusterin in left ventricular remodeling after myocardial infarction

Combined biomarker testing for the prediction of left ventricular remodelling in ST-elevation myocardial infarction

The role of microRNAs in myocardial infarction: from molecular mechanism to clinical application

Associations of circulating extracellular RNAs with myocardial remodeling and heart failure

Developing a panel of biomarkers and miRNA in patients with myocardial infarction for early intervention strategies of heart failure in West Virginian population

Expert review on the prognostic role of echocardiography after acute myocardial infarction

Wall motion score index and ejection fraction for risk stratification after acute myocardial infarction

Usefulness of the severity and extent of wall motion abnormalities as prognostic markers of an adverse outcome after a first myocardial infarction treated with thrombolytic therapy

Superiority of wall motion score index over left ventricle ejection fraction in predicting cardiovascular events after an acute myocardial infarction

Prognostic usefulness of the tricuspid annular plane systolic excursion in patients with acute inferior myocardial infarction

Right ventricular dysfunction and risk of heart failure and mortality after myocardial infarction

Usefulness of right ventricular fractional area change to predict death, heart failure, and stroke following myocardial infarction

Independent prognostic importance of a restrictive left ventricular filling pattern after myocardial infarction: an individual patient meta-analysis: Meta-Analysis Research Group in Echocardiography acute myocardial infarction

Noninvasive estimation of left ventricular filling pressure by E/e′ is a powerful predictor of survival after acute myocardial infarction

Left ventricular post-infarct remodeling: implications for systolic function improvement and outcomes in the modern era

Prediction of all-cause mortality and heart failure admissions from global left ventricular longitudinal strain in patients with acute myocardial infarction and preserved left ventricular ejection fraction

Value of three-dimensional strain parameters for predicting left ventricular remodeling after ST-elevation myocardial infarction

Predictive value of four-dimensional strain echocardiography for adverse cardiovascular outcomes in ST-elevation myocardial infarction patients treated with primary percutaneous coronary intervention

Impact of area strain by 3D speckle tracking on clinical outcome in patients after acute myocardial infarction

5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction

Prevalence and predictive value of microvascular flow abnormalities after successful contemporary percutaneous coronary intervention in acute ST-segment elevation myocardial infarction

Dobutamine stress echocardiography for risk stratification after myocardial infarction

Relationship between infarct size and outcomes following primary PCI: patient-level analysis from 10 randomized trials

Determinants and prognostic value of cardiac magnetic resonance imagingderived infarct characteristics in non-ST-elevation myocardial infarction

Relationship between microvascular obstruction and adverse events following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an individual patient data pooled analysis from seven randomized trials

Persistent microvascular obstruction after myocardial infarction culminates in the confluence of ferric iron oxide crystals, proinflammatory burden, and adverse remodeling

Chronic manifestation of postreperfusion intramyocardial hemorrhage as regional iron deposition: a cardiovascular magnetic resonance study with ex vivo validation

ST-segment-elevation myocardial infarction: relation to microvascular obstruction and prognostic significance

Intramyocardial haemorrhage and prognosis after ST-elevation myocardial infarction

Impact of multiple myocardial scars detected by CMR in patients following STEMI

Molecular imaging of cardiac remodelling after myocardial infarction

A multisensor algorithm predicts heart failure events in patients with implanted devices: results from the MultiSENSE study

Continuous wearable monitoring analytics predict heart failure hospitalization: the LINK-HF multicenter study

Intrathoracic impedance monitoring, audible patient alerts, and outcome in patients with heart failure

Remote management of heart failure using implantable electronic devices

Effects of remote monitoring on clinical outcomes and use of healthcare resources in heart failure patients with biventricular defibrillators: results of the MORE-CARE multicentre randomized controlled trial

-TIME study group*. Implant-based multiparameter telemonitoring of patients with heart failure (IN-TIME): a randomised controlled trial

Daily remote monitoring of implantable cardioverter-defibrillators: insights from the pooled patientlevel data from three randomized controlled trials (IN-TIME, ECOST, TRUST)

CHAMPION Trial Study Group. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial

Matrix metalloproteinases in myocardial infarction and heart failure

Blockade after myocardial infarction: systematic review and meta regression analysis

Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial

Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study

β Blocker treatment and other prognostic variables in patients with clinical evidence of heart failure after acute myocardial infarction: evidence from the AIRE study

Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials

Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction

Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure

The SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction-results of the survival and ventricular enlargement trial

Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients

OPTIMAAL Steering Committee, for the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial

Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHE-SUS trial

Direct effects of statins on cells primarily involved in atherosclerosis

Comparative effect of atorvastatin (80 mg) versus simvastatin (20 to 40 mg) in preventing hospitalizations for heart failure in patients with previous myocardial infarction

PROVE IT-TIMI 22 Investigators. Intensive statin therapy and the risk of

the PROVE IT-TIMI 22 study

Reduced risks of death and CHF are associated with statin therapy administered acutely within the first 24 h of AMI

Risk and predictors of readmission for heart failure following a myocardial infarction between 2004 and 2013: a Swedish nationwide observational study

Contemporary trends in heart failure with reduced and preserved ejection fraction after myocardial infarction: a community study

Nationwide trends in development of heart failure and mortality after first-time myocardial infarction

Heart failure after myocardial infarction